Especialista en prostatectomía robótica da Vinci en el Rambam Medical Center.
El profesor Kim Hyun-hoe es un cirujano especializado en cáncer urológico. Se especializa en cáncer de próstata y riñón y en cirugía robótica. Dirige el Centro de Cirugía Robótica y el Centro de Cáncer de Próstata y Riñón del Hospital Myongji. Realizó la primera laparoscopia de incisión única en Corea. En el SNUH, dirigió más de 2300 casos con da Vinci durante cinco años. Actualmente utiliza el sistema da Vinci Xi.
Posee un doctorado en medicina (MD), una maestría (MS) y un doctorado (PhD) de la Universidad Nacional de Seúl. Es exdirector del Centro de Cirugía Robótica y del Centro de Urología/Cáncer de Próstata del SNUH. Es expresidente de la Sociedad Coreana de Endourología y Robótica. Es miembro del consejo de la Asociación Urológica Coreana. Sus premios incluyen el premio a la mejor ponencia sobre laparoscopia/robótica de la WCE y la mejor ponencia de la KUA. También ha recibido varios reconocimientos académicos nacionales. Contribuye a la investigación de última generación sobre da Vinci junto con la Universidad Nacional de Seúl e Intuitive Surgical. Esta fue la primera colaboración de este tipo en Asia.
El Dr. Dotan es especialista en oncourología con un fuerte enfoque en la prostatectomía robótica da Vinci en el Centro Médico Assuta.
El médico es un especialista en urología altamente experimentado que se desempeña como Jefe del Departamento de Urología en el Hospital Quirónsalud Torrevieja desde 2017. Con un título médico y especialización de la Universidad Johannes Gutenberg en Alemania, el médico cuenta con una amplia experiencia clínica que se remonta a 2007. La experiencia del médico abarca la urología oncológica, las enfermedades de la próstata y las afecciones complejas del tracto urinario.
Un enfoque clave de la práctica del médico es la cirugía urológica robótica, específicamente utilizando el sistema quirúrgico Da Vinci para procedimientos de cáncer de próstata. El médico ha contribuido a la literatura académica, incluyendo capítulos en "Differentialdiagnose Urologie", y mantiene un fuerte enfoque en proporcionar atención de alta calidad tanto a pacientes locales como internacionales.
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Más de _doctor_3603_años_ de experiencia en el diagnóstico y tratamiento de trastornos de la articulación temporomandibular en el Centro Médico Hadassah.
El Dr. Yaacov Lawrence, MA, MBBS, MRCP, es jefe del Departamento de Oncología Radioterápica del Centro Médico Sheba. Cuenta con casi 30 años de experiencia en radioterapia de precisión y neurooncología.
Es experto en radioterapia avanzada y radiocirugía. Realiza radiocirugía estereotáctica para tumores cerebrales. Dirige el Programa de Cáncer Gastrointestinal de Sheba. También ofrece tratamiento de precisión para los cánceres de pulmón y próstata. Fue pionero en la radiocirugía del plexo celíaco para el dolor intenso por cáncer de páncreas.
Formación y credenciales: MA y MBBS (Cambridge y UCLH); MRCP (RCP); beca en Oncología Radioterápica (Thomas Jefferson University). Entre sus honores figuran el ASCO Young Investigator Award y ser Miembro de ASTRO (FASTRO). Ha publicado más de 280 trabajos. Es director del Centro de Oncología Radioterápica Traslacional y profesor asociado en la Universidad de Tel Aviv.
La Dra. Dorit Zilberman, MD, es uróloga sénior en el Centro Médico Sheba. Es pionera de la cirugía urológica robótica y mínimamente invasiva en Israel, con más de 20 años de experiencia. Su labor se centra en la oncología urológica, la cirugía robótica y laparoscópica, y la endourología. Ayudó a poner en marcha el programa de cirugía robótica da Vinci en Sheba. Su experiencia abarca los cánceres de riñón, vejiga y próstata, así como la litotricia láser para cálculos.
Realizó formación avanzada en cirugía laparoscópica robótica y endourología en el Centro Médico de la Universidad de Duke. Es profesora clínica sénior en la Universidad de Tel Aviv. Ha publicado más de 160 trabajos científicos. Ha recibido premios de las Asociaciones Urológicas de Israel y de Estados Unidos. Fue incluida en la lista de los Mejores Médicos de Forbes Israel en 2024. Es miembro de las Asociaciones Urológicas de Israel, Estados Unidos y Europa, y de la Sociedad de Endourología.
El profesor Jair Bar, MD, PhD, es oncólogo torácico y subdirector del Centro Oncológico del Sheba Medical Center. Dirige la Unidad de Oncología Torácica. Trata el cáncer de pulmón, incluidos los casos avanzados de cáncer de pulmón no microcítico. Su atención incluye oncología médica, radioterapia, inmunoterapia y terapia dirigida.
Dirige un laboratorio de investigación traslacional centrado en la resistencia a la inmunoterapia. Ha publicado sobre el metabolismo del cáncer en el aliento exhalado y sobre la inhibición de la angiogénesis en el cáncer de pulmón.
Preside el Grupo de Cáncer de Pulmón de Israel desde 2003. Es miembro de la Sociedad Israelí de Oncología Clínica y Radioterapia, de la Sociedad Estadounidense de Oncología Clínica y de la Asociación Estadounidense para la Investigación del Cáncer. Está certificado en Oncología Médica y Oncología Radioterápica. Es profesor sénior en la Universidad de Tel Aviv.
El Prof. Gil Raviv, MD, PhD, es director de la Unidad de Andrología del Centro Médico Sheba. Fue incluido entre los Mejores Médicos de Israel por Forbes en 2024. Es uno de los principales expertos en fertilidad masculina, medicina sexual y urología reconstructiva.
Su principal enfoque es la infertilidad masculina y la preservación de la fertilidad. Realiza análisis seminal avanzados según las normas de la OMS. Efectúa la obtención de espermatozoides testiculares (TESE, TESA, MESA) y la criopreservación de semen. También ofrece diagnóstico integral de fertilidad con análisis histológico.
Es profesor en la Universidad de Tel Aviv. Se formó en Siena, Roma y Tel Aviv. Completó una beca de subespecialización en infertilidad e impotencia en el Hospital Erasme. Recibió formación avanzada en cirugía uretral reconstructiva en Gante. Es miembro de la Asociación Europea de Urología, la Sociedad Internacional de Medicina Sexual y la Asociación Urológica de Israel.
Jefe de Urología en el Centro Médico Sheba – El Dr. Dotan se especializa en prostatectomía robótica y laparoscópica, ofreciendo precisión mínimamente invasiva.
El Dr. Nir Kleinmann, MD, dirige la Unidad de Endourología y Cálculos Renales del Centro Médico Sheba. Es experto en urología mínimamente invasiva y oncología urológica. Su enfoque se centra en el riñón y el tracto urinario superior. Fue reconocido entre los Mejores Médicos de Israel para 2025–2026 por Forbes y ResultMed.
Es pionero de la cirugía láser con preservación renal. Emplea un sistema de doble láser con neodimio y holmio para tumores complejos. Su experiencia incluye el carcinoma urotelial del tracto superior (UTUC), cáncer de riñón y de próstata, cálculos renales y la hiperplasia benigna de próstata (HBP).
Su investigación incluye el ensayo OLYMPUS sobre quimioablación para UTUC. Cuenta con más de 60 publicaciones.
Es urólogo con certificación del consejo en Israel. Es Fellow de la Sociedad Americana de Endourología y miembro de la Asociación Urológica Israelí y de la Asociación Europea de Urología (EAU). Completó subespecializaciones en Endourología y Cirugía Mínimamente Invasiva en la Universidad Thomas Jefferson, y en Investigación en Cáncer de Riñón en la Universidad McMaster.
El Dr. Gurkan Ozkan se especializa en enfermedades de la próstata y cirugías asistidas por robot en los hospitales Büyük Anadolu.
_doctor_969_años_ especializado en prostatectomía robótica y oncourología – el Dr. Colombo es miembro de la Sociedad Urológica de la República Checa.
El Dr. Sertkaya se especializa en Andrología y obtuvo el título 'FEBU' de la Asociación Europea de Urología. Realiza cirugías en hospitales afiliados.
Especializado en cirugías urológicas robóticas y laparoscópicas, el Dr. Ersoz aporta precisión a los tratamientos contra el cáncer de próstata en el Medipol Acibadem District Hospital.
El Dr. Tuncay Tas es cirujano urólogo en la clínica Safe Urology de Estambul. Es uno de los cinco primeros médicos a nivel mundial en publicar resultados sobre aplicaciones de P-Shot. El Dr. Tas se especializa en oncología urológica y salud sexual masculina. Completó su especialización en la Universidad de Heidelberg, Alemania. Su práctica se centra en la medicina regenerativa y la cirugía robótica para el cáncer.
El Prof. Dr. Ramazan Gökhan Atış se formó en urología robótica en la Universidad de Heidelberg, uno de los centros líderes en Europa en prostatectomía da Vinci.